Q&A
Exclusive interviews with industry leaders
-
Stock via Getty Images
In an era of big patent losses, drug launches need years of runway
Jim Lang, CEO of Eversana, explains the shifting commercial environment and how past drug launch failures are informing the future.
Amy Baxter • June 3, 2024 -
Permission granted by Daiichi Sankyo
The Enhertu effect: Daiichi’s plan to build on the success of its crown jewel
The CEO of Daiichi Sankyo’s American business explains why it could be poised to become a “top 10” cancer company.
Meagan Parrish • May 10, 2024 -
Permission granted by AstraZeneca
AZ oncology chief says AI can help solve cancer’s ‘ZIP code lottery’ as health disparities persist
Partnerships have been key to building the company’s AI capabilities and patient-focused R&D, said AstraZeneca’s head of U.S. oncology.
Michael Gibney • May 8, 2024 -
Courtesy of Alltrna
How a biotech exec is leveraging Big Pharma lessons to advance tRNA
Michelle Werner shares how the lessons from her resume — and personal experience — are driving her work with novel therapeutics.
Amy Baxter • April 29, 2024 -
Permission granted by Ovid Therapeutics
Neuroscience has entered a new era. Now it’s time for a ‘moonshot’ approach.
Dr. Jeremy Levin, CEO of Ovid Therapeutics, explains how scientific advances have converged to create a new era of drug development potential.
Meagan Parrish • April 26, 2024 -
Stock via Getty Images
AbbVie and Regenxbio’s ‘multibillion-dollar opportunity’ in vision loss gene therapy
After a successful mid-stage study, the companies aim to upend traditional wet AMD treatments with a one-time gene therapy.
Amy Baxter • April 24, 2024 -
Permission granted by eClinical Solutions
How pharma’s surging M&A is impacting the industry’s tech sector
As dealmaking in biopharma picks up, the CEO of eClinical Solutions sees an opportunity for clinical software companies to make acquisitions easier to close.
Michael Gibney • April 11, 2024 -
Permission granted by Verastem
With an ovarian KRAS combo ready for review, Verastem’s CEO is poised for the transition
As its FDA filing approaches, Verastem Oncology CEO Daniel Paterson wants to go from “The Little Engine That Could” to a major oncology player.
Michael Gibney • April 4, 2024 -
Permission granted by EMD Serono
To advance women’s leadership, an effort ‘has to be purposeful,’ says EMD Serono exec
Gender diversity in leadership “doesn’t just happen,” — it requires institutional change, from investing in women’s startups to providing more generous family leave.
Alexandra Pecci • April 1, 2024 -
Permission granted by Portal Bio
SQZ, Portal founder Armon Sharei on starting over in biotech
After his first biotech startup was sold off in parts, Sharei is applying the lessons he’s learned to a new company with a different business model.
Gwendolyn Wu • March 26, 2024 -
Permission granted by Boehringer Ingelheim
Why a pharmacist was tapped to spearhead ‘patient excellence’ at Boehringer Ingelheim
Deborah Reardon is leading a new pillar that asks, “Are we looking at this from a patient lens and not from a Boehringer lens?”
Alexandra Pecci • March 25, 2024 -
Permission granted by Wyss Institute
An ocean of answers in a single cell — how proteomics can lead to better drugs
New tools that allow researchers to separate single cells can help map the complex web of proteins that lead to disease, providing new targets for biopharma.
Michael Gibney • March 21, 2024 -
Stock via Getty Images
GSK has the U.S. shingles vaccine market cornered. A jab with fewer side effects could change that.
Curevo Vaccine is readying a phase 3 trial for a candidate it believes could have an edge over GSK’s blockbuster Shingrix.
Alexandra Pecci • March 19, 2024 -
Alex Wong/Getty Images via Getty Images
Former U.S. patent head on why federal march-in rights for drugs would be a ‘devastating’ mistake
A Biden administration proposal to seize patents for drugs deemed too pricey would have a ripple effect that cuts into the heart of innovation, says former U.S. PTO head Andrei Iancu.
Michael Gibney • March 14, 2024 -
Permission granted by Tarsus Pharmaceuticals
Into the unknown: Tarsus’ CEO on its launch strategies in a new disease category
The company scored a first-in-class nod for its eye med last year, which treats a common but frequently undiagnosed condition.
Meagan Parrish • March 8, 2024 -
iStock via Getty Images
Biogen partner NeuroSense seeks a role in the ALS revolution
Results from a mid-stage study for a new ALS drug have been strong, and NeuroSense is looking to join a small but sturdy wave of companies bringing new treatments to market.
Michael Gibney • Feb. 29, 2024 -
Maddie Meyer via Getty Images
For Moderna, COVID vaccines were a ‘proof of concept’ — now comes the big test
Following Moderna’s COVID-19 vaccine success, therapeutics head Dr. Kyle Holen discusses scaling mRNA development to bring candidates to the finish line in oncology and more.
Amy Baxter • Feb. 23, 2024 -
Permission granted by Mural Oncology
Why a former BMS exec calls her new CEO role ‘unfinished business’ in cancer care
With a focus on her “three pillars” of being a CEO, Caroline Loew explains how she’s building a new company culture at an Alkermes spinoff — and a pipeline that offers a next-gen approach to oncology.
Alexandra Pecci • Feb. 6, 2024 -
Permission granted by Amylyx
‘1 plus 1 equals 3’ — the co-CEO model in pharma
Amylyx Pharmaceuticals’ co-founders and co-CEOs Josh Cohen and Justin Klee explain their approach to dual leadership and why it can be a good fit in life sciences.
Meagan Parrish • Jan. 26, 2024 -
Permission granted by 4DMT
One biotech’s 3 gene therapy hurdles: delivery, delivery and delivery
4DMT’s David Kirn is looking to the future of gene therapy with delivery methods that change the paradigm.
Michael Gibney • Jan. 10, 2024 -
iStock via Getty Images
This biotech aims to expand the CRISPR toolkit for more disease targets in the liver and brain
Arbor Biotechnologies is looking past CRISPR’s recent regulatory wins and into the next stage of gene editing.
Michael Gibney • Dec. 19, 2023 -
Permission granted by Quita Highsmith
The many ‘myths’ of clinical trial diversity, and Genentech’s fight to disrupt them
Genentech’s chief diversity officer Quita Highsmith is on a crusade to prove that much of what the industry believes about clinical trial diversity is wrong.
Michael Gibney • Dec. 14, 2023 -
Permission granted by FNIH
A former CDC head on key R&D areas, public trust and if we learned anything from COVID-19
Dr. Julie Gerberding, now president and CEO of the Foundation for the National Institutes of Health, shares lessons learned from a long career in academic, public health and industry.
Meagan Parrish • Dec. 13, 2023 -
Permission granted by Adam Lenkowsky
Bristol Myers’ commercial chief on the industry’s ‘seismic’ changes over 27 years and what’s coming next
Adam Lenkowsky’s unique vantage point on the major transformations shaping BMS and the industry as a whole.
Michael Gibney • Dec. 12, 2023 -
Justin Sullivan via Getty Images
Patients who hide pills and advocacy offices that could get ‘raided’ — a Gilead leader on navigating global HIV
Gilead Sciences’ SVP of global patient solutions discusses how she’s managing some of the world’s most complicated health issues and what’s next in HIV innovation.
Alexandra Pecci • Dec. 11, 2023
